Condition: Colorectal Cancer · Sponsor: Memorial Sloan Kettering Cancer Center
The researchers are doing this study to find out whether tislelizumab is an effective treatment for people with colorectal cancer who are living in Nigeria. The researchers will also look at the safety of the study drug. All participants in this study will be treatment naïve (they have not yet received treatment for their cancer), and their cancer will be mismatch repair deficient (dMMR). dMMR cancer can happen when your cells are unable to repair mistakes made during the cell division process.
This description comes directly from the study's public registry record.
Fiyinfolu O Balogun, MD, PhD · 646-888-6964 · balogunf@mskcc.org
Peter Kingham, MD · 212-639-5260
Always discuss trial participation with your own doctor first.
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| Lagos University Teaching Hospital | Idi-Araba, Lagos, Nigeria | Not Yet Recruiting |
| Obafemi Awolowo University Teaching Hospital | Ile-Ife, Nigeria | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06529523